antimitotic agent-2

Antimitotic agent-2 (Compound 1) is an antimitotic agent that inhibits the proliferation of human epidermal cells. It may be used in the treatment of hyperproliferative skin disorders.

2-Methoxyestradiol (2-ME2) is an orally bioavailable estradiol metabolite with potential antineoplastic activity. 2-Methoxyestradiol inhibits angiogenesis by reducing endothelial cell proliferation and inducing endothelial cell apoptosis. This agent also inhibits tumor cell growth by binding to tubulin, resulting in antimitotic activity, and by inducing caspase activation, resulting in cell cycle arrest in the G2 phase, DNA fragmentation, and apoptosis.

PYRIB-SO 2 is an effective antimitotic (mitotic) agent that exhibits antiproliferative activity and induces cell cycle arrest at the G2/M phase. It disrupts and reduces microtubule structures by binding to the colchicine-binding site (C-BS) on α, β-tubulin.

1. Santalol has good antibacterial, anti-oxidation and anti-tumor activities. 2. α-Santalol is a potent antimitotic agent induced by interference with microtubule assembly. 3. α-Santalol shows a significant antifungal effect against a dermatophytic fungus

Maytansinoid B, an ADC cytotoxin, conjugates with antibodies to create antibody-drug conjugates (ADCs). This antimitotic agent binds to tubulin, inhibiting microtubule assembly, and induces G2/M arrest in the cell cycle, leading to apoptosis [1] [2].

2-Methoxyestradiol (Standard) is a reference standard for research and analysis in studies involving 2-Methoxyestradiol. 2-Methoxyestradiol (2-ME2) is an orally bioavailable estradiol metabolite with potential antineoplastic activity. 2-Methoxyestradiol inhibits angiogenesis by reducing endothelial cell proliferation and inducing endothelial cell apoptosis. This agent also inhibits tumor cell growth by binding to tubulin, resulting in antimitotic activity, and by inducing caspase activation, resulting in cell cycle arrest in the G2 phase, DNA fragmentation, and apoptosis.